Form D · Other Technology
Talus Bioscience, Inc.
Seattle, WA · CIK 0002033246
Offering snapshot reported Aug 12, 2024 · SEC filing
- Reported sold
- $9.42M Offering amount: $11.3M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 29, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 12, 2024 | Initial | $9,423,516 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-521283
Source: Form D, filed Aug 12, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Omri Amirav Drory | Director |
| Michelle Briscoe | Executive |
| Alex Federation | Director, Executive, Promoter |
| Lindsay Pino | Director, Executive |
| J. Seth Strattan | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
550 17th Avenue, Suite 550
Seattle, WA, 98122
Seattle, WA, 98122